Intestinal transit modulation

Intestinal transit modulation refers to the physiological regulation of the speed and efficiency with which luminal contents move through the gastrointestinal tract (NIH, 2023). This process is primarily governed by the enteric nervous system (ENS) and the coordinated contraction and relaxation of smooth muscle layers (StatPearls, 2023). It is essential for proper digestion, nutrient absorption, and the timely elimination of waste. Dysregulation of this process is a hallmark of functional gastrointestinal disorders, including irritable bowel syndrome (IBS) and chronic idiopathic constipation (Mayo Clinic, 2024). Pharmacological modulation involves targeting specific receptors such as 5-HT4 serotonergic receptors to enhance motility or mu-opioid receptors to reduce it (PubMed, 2022). Additionally, secretagogues like linaclotide can accelerate transit by increasing intestinal fluid volume via ion channel activation (FDA, 2021). Effective modulation is a key therapeutic goal to alleviate symptoms like bloating, abdominal pain, and irregular bowel habits. Because 'Intestinal transit modulation' describes a physiological process or therapeutic effect rather than a specific protein or molecule, it is classified as a phenotype or mechanism rather than a discrete molecular target.

Other names

Gastrointestinal motilityGut transitBowel transitIntestinal motility regulation

Modulation of intestinal transit is achieved through the activation or inhibition of various molecular pathways, including 5-HT4 receptor agonism to promote motility, mu-opioid receptor agonism to slow transit, and the activation of chloride channels (e.g., ClC-2 or CFTR) to increase intestinal fluid secretion and accelerate transit.